The purpose of this study was to determine if magnetic resonance imaging (MRI) could quantify a difference in clitoral response following administration of a vasoactive medication, in 12 women with female sexual arousal disorder (FSAD). Subjects were entered into a double-blind, randomized two-way crossover study of sildenafil 50 mg vs placebo administered 1 h prior to genital MRI. Each subject underwent two MR studies, performed while subjects viewed alternating segments of nonerotic and erotic video. MR images were analyzed for change in clitoral volume during each session. The mean change in clitoral volume for the entire group was higher in the sildenafil MRI session (1282 mm 3 ) compared with placebo (849 mm 3 ) but did not reach statistical significance (P ¼ 0.064). Comparison using analysis of variance between the two sessions for each individual subject revealed a significant increase in clitoral volume following sildenafil compared with placebo in 6 of 12 subjects, no significant change in either imaging session in three subjects and in three subjects, there was a robust clitoral response in both MR sessions. In conclusion, MR measurements of clitoral volume can provide an objective measure of engorgement change following a vasoactive medication in women with FSAD.
Introduction
One of the most problematic issues in investigations of the female sexual response is the limited availability of a reliable physiological measure of genital arousal. In men, penile tumescence and rigidity can objectively document the integrity of the genital sexual response. 1 In women, this is not as easily performed because the genital response is primarily internal and not directly visible. Measurements of clitoral arterial blood flow, 2 vaginal venous blood flow, 3 genital thermography 4 and neural integrity 5 all can provide a narrow glimpse of the sexual response by assessing a very specific aspect of genital physiology, but none gives an anatomic and physiological assessment of the genital organs such as the clitoris. Clitoral engorgement is an important part of the genital sexual arousal response. It is the only organ 'which is totally limited in physiologic function to initiating or elevating levels of sexual tension'. 6 Female sexual arousal disorder (FSAD) is defined as persistent or recurrent inability to attain (or to maintain until completion of the sexual activity) an adequate genital lubrication-swelling response of sexual excitement, which causes marked distress or interpersonal difficulty. 7 In prior studies, we have developed and validated dynamic genital magnetic resonance imaging (MRI) techniques that non-intrusively demonstrate a significant increase in female genital blood volume and clitoral size during sexual arousal 8 ( Figure 1 ). These studies demonstrated excellent intrasubject reproducibility in healthy women without sexual arousal difficulties. For the first time, a comprehensive assessment of the female genitals was possible during sexual arousal. The purpose of the present exploratory study was to evaluate our MRI techniques in determining clitoral volume changes in a group of women with documented FSAD. These women were blindly administered a vasoactive medication or placebo in a randomized order in two serial studies, to determine if MRI could quantify a difference in response.
Methods
After signing an informed consent for the study, which was approved by our Human Subjects Review Committee, 12 subjects with FSAD were enrolled in the study. The ages ranged from 31 to 58, eight were premenopausal and four were postmenopausal.
After a history and physical examination (including pelvic examination), all subjects received blood, urine and hormonal screening. Hormone levels included estradiol and free testosterone. Exclusion criteria included abnormal hormonal status; pregnancy, delivery or breast feeding within preceding 6 months; use of hormonally active medications; primary sexual pain, orgasmic or desire disorder; and medical conditions or medications that may predispose to arousal difficulties.
A detailed sexual history interview was conducted including an extensive questionnaire. The diagnosis of FSAD was determined from the results of the history. Inclusion criteria required that the subject had FSAD for at least 6 months, and exclusion criteria (in addition to those listed above) were as follows: never having had a satisfactory sex life, situational sexual dysfunction, treatment for major psychiatric disorder with in 12 months of the study, major psychological or sexual disorder, which is considered to be the primary diagnosis explaining FSAD or inability to participate in the study due to claustrophobia or other contraindications to MRI.
All subjects were entered into a double-blind, placebo-controlled, randomized two-way crossover study of sildenafil (50 mg) vs placebo administered 1 h prior to undergoing an MRI. Thus, each subject underwent two MR studies (sessions 1 and 2). If the subject was premenopausal, the scans were performed during days 7-12 of the menstrual cycle. Sildenafil was administered to determine if a vasoactive substance could enhance the vasocongestive response as measured by MR. MR studies were performed while subjects viewed 15 min of baseline nonerotic video clips followed by 15 min of erotic video, finishing with 15 min of nonerotic video. The audio-video sexual stimulation presentation was displayed using a fiber optically coupled device and pneumatic headphones (Avotec Inc., Stuart, FL, USA). Different video clips were shown for each session. Subjective arousal levels were assessed by a 7 item Likert scale questionnaire (Appendix 1) administered immediately prior to and following each MR imaging session.
MR technique
The MR technique has been described previously. 9 Imaging was acquired using a 1.5 Tesla Horizon Echospeed MRI scanner (General Electric, Milwaukee, WI, USA) and an asymmetrical pair of custom-phased array coils built in our laboratory consisting of a 10 cm two-coil array placed anterior to the pubic symphysis, Figure 1 Axial image of T1-weighted MRI of clitoris and surrounding structures (a) during neutral video clip, (b) during erotic video clip (arousal). The clitoris is the wishbone-shaped structure. The two bulbs converge in the midline to form the boomerang-shaped structure situated immediately dorsal to the clitoral crura. The increased signal intensity in both structures during arousal represents increased blood volume within these structures. B, bulb; C, clitoral body/crus.
Influence of PDE5 inhibitor on clitoral volume response in women with FSAD CC Yang et al and a 20 cm phased array pair placed beneath the subject's buttocks. Rapid T1-weighted low-resolution localizer images of the pelvic structures were obtained in axial, coronal and sagittal planes. From these localizer images, a T2-weighted three-dimensional fast spin echo sequence was accurately centered to encompass the genital structures and vulva. A threedimensional fast spin echo sequence acquired in an axial plane was used for the dynamic imaging sequences and the parameters consisted of the following: TR ¼ 2000 msec, TE ¼ 104 msec, an echo train length of 48 and 1 signal average. The field of view was 24 cm and 19 partitions (slices) were acquired at 3 mm intervals. Fat saturation was used to suppress signal from subcutaneous and deep fat. This sequence was repeated at 3-min intervals while subjects viewed the 45-min video presentation to obtain serial MR images displaying changes in clitoral engorgement over time.
Image analysis
The images were analyzed offline by a single observer, who was blinded to the subjects' clinical information, whether the subject had received sildenafil or placebo, as well as whether the video segment was erotic or neutral. MR images for each session were analyzed for change in clitoral volume over the time of the MR session, using threedimensional reconstructions of the MR images. Percent clitoral volume change was calculated between the mean baseline volume and mean volume during video arousal. Clitoral volume change was analyzed both for the entire group as well as for each subject individually comparing the two sessions and then correlating with administered drug (sildenafil or placebo). This was tested with analysis of variance at the 5% level of significance.
Results
All of the screened subjects were able to complete the study.
Clitoral volume measurements
These analyses revealed a measurable increase in clitoral volume response following sildenafil compared with placebo in 6 of 12 subjects (Figure 2 ). There was poor clitoral response in either imaging session in three subjects (Figure 3) . In three subjects, there was a robust and equal clitoral response in both MR sessions (Figure 4 ) similar in pattern and clitoral volume change (84-137%) to that seen in healthy volunteer women in prior studies.
Clitoral volume during the neutral video in seven subjects was somewhat variable from session 1 to session 2, possibly due to mild engorgement of the clitoris from the effects of sildenafil. In these subjects in whom a definite and consistent difference was noted, the higher volume was in the sildenafil MRI study session. However, the measurements were not taken as absolute values in the analysis for arousal response; intrasubject differences in baseline volume measurement were minimized by evaluating percent clitoral volume change between neutral and aroused states for each MRI Subjective arousal. The mean arousal score for session 1 was the same as for session 2 (3.2 vs 3.3 out of 7). Subjects generally reported the same level of arousal for both sessions, with the greatest difference of 2 points in one subject. In previous studies using this arousal scale, healthy women without complaints of sexual dysfunction reported mean arousal scores of 4.39. In this study, two women scored both their sessions at 5.0 or higher. One of these women reported an arousal score of 6.0 for one session, and 7.0 for another session. Two other subjects reported one of two of their sessions at 5.0 or higher.
The mean arousal score of both video sessions for the group that had no significant clitoral volume change in both sessions was 1.3 (range 1.0-1.7). Of the group with an increased clitoral volume response during the erotic video with sildenafil, the mean arousal score was 3.1 (range 1.0-5.7). The group that had a robust clitoral volume change during the erotic video in both sessions had a mean arousal score of 4.9 (range 3.7-7.0).
Discussion
The primary conclusion of this exploratory study is that MRI can document responses in women with FSAD. The fact that women who serve as their own Influence of PDE5 inhibitor on clitoral volume response in women with FSAD CC Yang et al controls can have measurable changes on MRI shows that this is a promising method to study differential physiologic arousal response following drug therapy in women with FSAD. No other imaging or diagnostic modality can give this kind of detailed anatomic and physiological data without anatomic distortion. Albeit expensive and labor intensive, the technique is durable and reliable in its depiction and quantification of physiological changes. From the perspective of the cost involved in a dynamic MRI study such as this, it is important to keep in mind that this technique is not being advocated for use as a routine diagnostic evaluation. Rather, this is being developed as a tool for evaluating response to new medication therapies that might be developed in the future. In that role, the MRI technique described is cost effective in supplying important unique and quantifiable data in a more time-efficient manner compared with current methodologies that heavily rely on subjective questionnaires and journal logs over protracted time periods to judge effects on sexual response. In addition, this technique has the added benefit that it may help to better understand the functional physiology of female sexual response patterns.
Recognizing that all interpretations are limited from exploratory data, we have noted several interesting secondary findings, which may eventually be confirmed in broader studies. The most notable of these is that not all the subjects responded similarly, which may reflect the heterogeneity of the female sexual response, as well as of FSAD. This point cannot be overemphasized. There are obviously many factors contributing to sexual arousal, some of which are not quantifiable on physiological measures. Defining subcategories of both normative sexual arousal and FSAD will be necessary to interpret the psychosocial and physiological data in a meaningful manner. This does not invalidate the usefulness of MRI in examining the female sexual response; in the contrary, MRI has objectively demonstrated the variable physiological responses in women with a single diagnosis, suggesting that the diagnosis be re-examined for subtyping.
One manifestation of the variability of FSAD is that 25% (3 of 12) of the subjects showed robust changes in clitoral volume in response to audiovideo sexual stimulation without sildenafil, suggesting that some women with FSAD do not have a genital blood flow problem. Furthermore, the use of sildenafil did not improve subjective arousal in the group as a whole, though there was some general correspondence between clitoral volume changes and subjective arousal. It is well known that there is a very significant psychological/emotional aspect to female sexual arousal, which a vasodilating agent is not able to affect.
Second, it is interesting to note that two women reported arousal scores in the 'normal' range in both sessions, with one reporting very high arousal scores for both sessions. Both these women were diagnosed to have FSAD based on our earlier stated criteria. This could be interpreted to mean that either they do not have FSAD (despite the conclusion from an in-depth interview, and the subject's self-report), or they may have FSAD with their partner, not manifesting during audio-video sexual stimulation. This latter situation needs to be kept in mind when addressing and treating FSAD.
This study was not designed to evaluate the effects of medication on female genitalia, but to look at the feasibility of discerning differences in genital engorgement as a result of a vasodilating drug, during sexual arousal in women with FSAD. Although sildenafil has no significant efficacy in a broad population of women with FSAD, 10 its vasoactive properties provide a model for testing measurement methods. Future investigations with MRI may include a larger, multicenter study; evaluating medications that potentially have greater efficacy in FSAD; and examination of other sexually responsive tissues such as the bulb.
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Conclusion
Magnetic resonance imaging measurements of clitoral volume in response to an audio-visual sexual stimulus can provide an objective measure of engorgement change following a vasoactive medication in women with FSAD. FSAD is a heterogenous entity, and will require better definition, from both a physiological as well as a psychological perspective.
